Leaders and Key Contacts

Leaders and Key Contacts.

Faster, better, smarter starts at the top… and keeps going!

#TeamYellow leverages strategic acumen, pharmaceutical expertise, and intercultural proficiency to make your vision a reality.

Below you’ll find information about our key management and technical team members.

Arriello’s founders & directors.

Alan White
CEO and Founder

Alan's role is to lead the organization with the drive and energy required to continue to make the company a success. He has a close connection to the Commercial activities of the company, working closely with the Commercial Operations Director and Chief Marketing Officer.

Alan has worked in the Pharmaceutical space since 2005 but also has commercial experience in the IT, architectural and lighting sectors. It is this broad range of experiences that gives Alan a different perspective on the industry he works in.

Common to all these areas is his ability to problem solve and take a common-sense approach to situations. He has a close affiliation with clients – a people’s person.

Anna Lukyanova
COO and Founder

Anna oversees our Pharmacovigilance, Regulatory and Project Management teams, balancing keeping our clients super happy whilst developing and nurturing our growing team.

She has worked in the pharmaceutical industry since 2005 in the business development and operational areas.

Anna acquired her customer centric approach from the hospitality sector where she received extensive training and experience after graduating from university in the US.

She is a strong believer in leading by example and would not expect anyone to do something she was not prepared to do herself.

Michael Sandys
Finance Director

Michael has been with the organization since 2011 and is currently responsible for ensuring that the group remains compliant in all contractual aspects. 

He is a Chartered Accountant with a wealth of experience in contract management as well as accounting and taxation. 

He graduated from EY with an FCA in Accounting. 

Michael is the Intragroup Finance Director at Arriello, based at our headquarters in Dublin, Ireland. 

André van de Sande
Executive Consultant to the Board

André has over 30 years of Life Sciences experience leading organizations ranging from 40 to 1,400 employees as CEO, Managing Director and as Regional Vice President. Most recently he was CEO of Life Science Consultancy company Xendo Holding.

He has extensive change management experience and broad Non-Executive and Advisory board experience and is a regular lecturer and chair.

André holds an MBA degree from Tilburg University, The Netherlands and a MSc in Management from Purdue University, USA.

Technical consultants & directors.

Kieran O'Donnell
Vice President, Global Drug Safety

Kieran has over 20 years of broad PV experience in pharma, CROs, and management consultancy.

He is also an experienced auditor and QPPV with over 15 years of experience in those roles.

Kieran has lead PV functions at VP & Director level for over 12 years, and during that time has led multiple and successful change projects. 

This wealth of experience and knowledge helps Kieran understand and anticipate client needs, and tailor PV solutions accordingly. 

Prabjot Hunjan
Director of Global Drug Safety

Prabjot has over 16 years of PV experience both in CROs and pharma and has six years in management within a leading UK ophthalmology chain.

His CRO & pharma experience includes director-level management, leading and developing the Pharmacovigilance function whilst delivering Pharmacovigilance Quality and Process Improvements.

He is also a trained auditor and experienced in EU GDPR as a Data Protection Officer.

Helen Lowe
Auditing and Quality Assurance Director

Helen has over 16 years experience within the pharmaceutical and biological sector and has extensive global PV QA auditing experience with local operating companies, affiliates, co‐developments, marketing/license partnerships, distribution and regulatory due diligence.

She has conducted numerous GCP clinical investigator site audits, medical information audits, regulatory audits, and has assisted with computer system validation audits. She has also participated in or managed several health authority inspections (including FDA, BfArM, MHRA, AEMPS).

Peter Embley
Chief Regulatory Officer

Pete has over 24 years of experience working across the Pharmaceutical, CRO and Consulting Industries.

Grounded in UK and European regulatory activities, and in particular, developing and executing strategies for generic and early-stage development programs, his responsibilities have included, but not limited to; Agency Scientific Advice, feasibility of accelerated tools such as EMA-PRIME, MHRA-ILAP, CMC, PIP, Market-Access and MAA due-diligence.

More recently, Pete has supported US IND/EU CTA and Chinese IND submissions, leading a team for the development and execution of Early (& Post-Trial) Access Programs.

Sandra Lourenço
Head of Regulatory Affairs

Sandra holds a chemistry degree and has 20 years of pharmaceutical industry and consultancy experience. She started her work as a Scientific Investigator in the wine industry, and moved into pharmaceutical development, interacting, and contributing at the earliest stage of the medicinal lifecycle.

In 2007 she moved into regulatory affairs and has submitted over 500 new MAs in the EU with national and European procedures, which included CMC (Chemistry, Manufacturing and Control) construction, LoDs preparation and revision and the consequent lifecycle maintenance of those products after approval.

Our pharmacovigilance advisory board.

Dr. John Price, Dr. Judith M. Sills, Dr. Panos Tsintis and Dr. Eric Caugant head up Arriello’s pharmacovigilance advisory board, bringing their extensive global experience to help shape and direct our future pharmacovigilance strategy and operations. 

Based evenly across the US and Europe, each of our board members commands a unique high-level industry insight, having worked with or for the EMA, FDA, MHRA, ICH, CIOMS and many other key organizations on national and global projects and initiatives.

John Price (Dr.)
US based PV expert.

Dr. John Price is an executive physician with deep experience gained from over 25 years working across the breadth of regulatory affairs and pharmacovigilance worldwide.

He has created and led high-functioning global departments for pharmacovigilance, regulatory and clinical operations, medical writing and drug development, and held senior roles in the UK Medicines Control Agency (now MHRA), Pfizer, J&J, Alexion Pharmaceuticals, and academia.

Judith M. Sills (Dr.)
US based PV expert.

Dr. Judith M. Sills, Pharm.D. is President of JM Sills Consulting LLC, specializing in pharmacovigilance and benefit-risk management.

Dr. Sills has over 30 years of experience in pharmacovigilance in the pharmaceutical industry, FDA, and consulting.

Prior to establishing a consulting practice in 2018, she was Vice President and Head, Global Pharmacovigilance at The Medicines Company.

Panos Tsintis (Dr.)
EU based PV expert.

Dr. Panos Tsintis has a total of over 30 years of pharmacovigilance, regulatory affairs and pharmaceutical medicine experience, from drug development to post-marketing.

Between 2002 and 2008 he was Head of Pharmacovigilance and Post-Authorisation Safety and Efficacy Sector at the European Medicines Agency (EMA).

He has also held senior positions at the UK MHRA as well as in the pharmaceutical industry.

Eric Caugant (Dr.)
EU based PV expert.

Dr. Eric Caugant has over 25 years of experience in Pharmacovigilance, Drug Safety, Risk Management, and more broadly Pharmaceutical Medicine.

In 2017, he founded Pharmacovigilance Systems Consulting (PhVSC).

Prior to this Eric held senior positions, in various pharmaceutical and biotech companies, such as Alexion, Bayer Lilly, Wyeth and also the French Ministry of Health.

Our regulatory advisory board.

Dr. Howard Levy, Peter Kennerly and Dr. John Price form Arriello’s founding regulatory advisory board, with a wealth of experience and knowledge to help define the future of our regulatory affairs services.

As with our PV advisory board, they bring their unique perspectives from both the US and Europe in clinical and post-marketing scenarios for biotechs and large pharma. They also bring their insights from direct experience with the EMA, FDA and many other key industry bodies.

Howard Levy (Dr.)
US based Clinical expert.

Dr. Howard Levy, M.B. BCh., Ph.D., M.M.M. has over 20 years of experience in Clinical Development, Medical and Regulatory Affairs in the pharmaceutical industry and has been Chief Medical Officer at 4 Biotechnology companies, and has consulted for numerous biotechnology start-up companies.

He has been involved in the development of 6 approved agents in the USA and Europe.

He is currently Chief Medical Officer at Ampio Pharmaceuticals and maintains a robust consulting practice.

Peter Kennerly
CEO Agos Pharma.

Pete has over 35 years’ experience in drug development and product safety oversight. He is a former Senior Medical Assessor for the UK Regulatory Agency with extensive experience in negotiations with European national regulatory authorities as well as the European Medicines Agency and experience in safety negotiations with the FDA.

Pete has worked in small and large pharma, establishing global drug safety processes with oversight of multiple successful regulatory procedures for rare and orphan products.  He is an experienced chairman of Data Monitoring Committees, expert panels and a published medical scientist.

John Price (Dr.)
US based PV expert.

Dr. John Price is an executive physician with deep experience gained from over 25 years working across the breadth of regulatory affairs and pharmacovigilance worldwide.

He has created and led high-functioning global departments for pharmacovigilance, regulatory and clinical operations, medical writing and drug development, and held senior roles in the UK Medicines Control Agency (now MHRA), Pfizer, J&J, Alexion Pharmaceuticals, and academia.